II. Mechanism

  1. Monoclonal antibodies (PCSK9 Inhibitor)

III. Indications

  1. Severe familial Hypercholesterolemia (e.g. LDL Cholesterol >190 mg/dl)

IV. Background

  1. Available in U.S. as of 2015

V. Preparations

  1. Praluent (Alirocumab)
  2. Repatha (Evolocumab)

VI. Efficacy

  1. Lower LDL Cholesterol up to 60%
  2. See disadvantages below

VII. Disadvantages

  1. Very expensive agents ($14,000 per year)
  2. New, with only short-term data
    1. Unknown longterm safety
    2. Unknown vascular disease prevention outcomes (contrast with proven Statin efficacy)

Images: Related links to external sites (from Bing)

Related Studies (from Trip Database) Open in New Window

Cost: Medications

praluent (on 8/17/2016 at Medicaid.Gov Survey of pharmacy drug pricing)
PRALUENT 75 MG/ML PEN $554.12 per ml
repatha (on 8/17/2016 at Medicaid.Gov Survey of pharmacy drug pricing)
REPATHA 140 MG/ML SURECLICK $520.89 per ml